Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSCN1 | Q16658 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8279652 | 0.81 | FSCN1 (0.44) | FSCN1TSHRNPC1ADORA2BRAB9A | |
| SCHEMBL5481067 | 0.75 | FSCN1 (0.49) | FSCN1TSHRNPC1RAB9ACYP1A2 | |
| SCHEMBL23505871 | 0.69 | RAB9A (0.61) | TSHRNPC1ADORA2BRAB9ACYP1A2 | |
| SCHEMBL15521850 | 0.69 | FSCN1 (1.00) | FSCN1TSHRCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10654215 | 0.67 | ADORA2B (1.00) | TSHRADORA2BSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL10367385 | 0.66 | RAB9A (0.46) | TSHRNPC1RAB9ACYP1A2CYP2C9 | |
| SCHEMBL4873272 | 0.66 | HDAC6 (0.68) | TSHRSMN1; SMN2ALDH1A1MAPK1KMT2A | |
| Hydrochloric Acid SCHEMBL10872008 | 0.66 | ADORA2B (0.97) | TSHRADORA2BSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL10369777 | 0.65 | NPC1 (0.46) | TSHRNPC1RAB9ACYP1A2CYP2C9 | |
| SCHEMBL11983579 | 0.65 | NPC1 (0.59) | TSHRNPC1ADORA2BRAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010019-A1 | Reactive Oxygen Generating Enzyme Inhibitor With Nitric Oxide Bioactivity and Uses Thereof | DUKE UNIVERSITY (US) | 2010-01-14 | — | — | US | disclosed |
| US-7625907-B2 | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof | DUKE UNIVERSITY (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1737867-A4 | REACTIVE OXYGEN GENERATING ENZYME INHIBITOR WITH NITRIC OXIDE BIOACTIVITY AND USES THEREOF | UNIV DUKE (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1737867-A1 | REACTIVE OXYGEN GENERATING ENZYME INHIBITOR WITH NITRIC OXIDE BIOACTIVITY AND USES THEREOF | Duke University (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060194820-A1 | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof | DUKE UNIVERSITY (US) | 2006-08-31 | — | — | US | disclosed |
| US-7067659-B2 | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof | DUKE UNIVERSITY (US) | 2006-06-27 | — | — | US | disclosed |
| WO-2005105806-A1 | REACTIVE OXYGEN GENERATING ENZYME INHIBITOR WITH NITRIC OXIDE BIOACTIVITY AND USES THEREOF | DUKE UNIVERSITY (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050239807-A1 | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194820-A1 | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof | NOS1, NOS2, SOD1 | FSCN1 3330/4885TSHR 4534/4885NPC1 2090/4885 |
| US-20050239807-A1 | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof | NOS1, SOD1, NOS3 | FSCN1 4240/4885TSHR 4184/4885NPC1 2558/4885 |
| US-20100010019-A1 | Reactive Oxygen Generating Enzyme Inhibitor With Nitric Oxide Bioactivity and Uses Thereof | NOS1, NOS2, SOD1 | FSCN1 3330/4885TSHR 4534/4885NPC1 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.